Tumor imaging using 68Ga-octreotide

Tumor imaging using 68Ga-octreotide - Somatostatin receptor scintigaraphy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004444

Enrollment

800

Registered

2011-01-01

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuroendocrine tumor non-FDG-avid tumor

Interventions

68Ga-DOTA-TOC, which is synthesized in our institute, is intravenously administered. 30-60 min later, whole body scanning is performed using an inline PET/CT system.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are suspected of having tumors with somatostatin receptors, and are requested for localization, staging or restaging, and moinitoring therapy response.

Exclusion criteria

Exclusion criteria: 1. Communication disturbance 2. Extremely poor physical status 3. Informed consent not available

Design outcomes

Primary

Measure	Time frame
Diagnostic accuracy and clinical impact of PET/CT with 68Ga-DOTA-TOC	—

Countries

Japan

Contacts

Public ContactYuji Nakamoto

Kyoto University Hospital Department of Diagnostic Radiology

ynakamo1@kuhp.kyoto-u.ac.jp075-751-3538

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026